This event is open exclusively to Capitol Hill staff members.
This conversation will focus on how the user fee reauthorization process works and lessons from previous reauthorization cycles.
This event will feature a discussion among former Energy and Commerce Committee FDA Counsels on the upcoming reauthorization of the FDA’s user fee programs for prescription drugs and biologics, medical devices, generic drugs, and biosimilars. The conversation will focus on how the user fee reauthorization process works and lessons from previous reauthorization cycles.
When: March 2nd, 12:30–1:30 PM
Where: CVC 268
Every five years Congress reauthorizes FDA’s user fee programs for medical programs. This briefing will provide an overview of the legislative process, stakeholder engagement, and key considerations as the next reauthorization cycle approaches.
Panelists:
· Ryan Long — Paragon Health Institute
· Clay Alspach — Leavitt Partners
· John Stone — BGR Group
· Kristin Seum — Vertex Pharmaceuticals
This event is open exclusively to Capitol Hill staff members.
